Cash and cash equivalents as of March 31, 2025 were approximately $16.4 million and total obligated grant funds remaining from the National Institute of Aging, a division of the National Institute of Health were $47.0 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics presents results at AD/PD 2025 on CT1812
- Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer’s and Dementia Indications
- Cognition Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
- Cognition Therapeutics Earnings Call: Progress Amid Challenges
- Cognition Therapeutics price target lowered to $8 from $11 at Chardan